source
- City Therapeutics raises $200 million in IPO, becoming 26th biotech listing of 2026City Therapeutics announced that it has completed a $200 million initial public offering, making it the 26th biotech to go public in 2026. The company, based in Kendall Square, will begin trading…
- Novartis ends mid-stage Fabhalta trial in lupus nephritis citing strategic considerationsNovartis has terminated its mid-stage trial of Fabhalta (iptacopan) in patients with lupus nephritis, according to a federal clinical trials registry. The company said the decision was driven by s…